Dr. Peggy Sotiropoulou joined Celyad Oncology in October 2017, bringing 15 years of experience in oncology and immuno-oncology. Dr. Sotiropoulou joined Celyad Oncology initially as R&D Manager, evolving to R&D Director in October 2018. In May 2020, Dr. Sotiropoulou was appointed Head of R&D, where she oversees a broad-range research program that aims to develop new strategies in CAR T cell designs to target hematological and solid malignancies. Dr. Sotiropoulou received her PhD in Cancer Immunotherapy from the Medical faculty of the University of Crete, prior to moving to the group of Professor Cédric Blanpain in the Université Libre de Bruxelles to investigate cancer development and the role of cancer stem cells. Prior to joining Celyad Oncology, Dr. Sotiropoulou was tenured Research Associate Professor in the Université Libre de Bruxelles, leading cutting-edge research on the response and sensitization of recalcitrant tumors to therapy.